Ardelyx, Inc. (ARDX)

7.77 -0.29 (-3.60%) 收市：04:00PM EDT

Ardelyx, Inc.

400 Fifth Avenue
Suite 210
Waltham, MA 02451
United States
510 745 1700
https://www.ardelyx.com

版塊: Healthcare
行業: Biotechnology
全職員工: 267

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Michael G. Raab	President, CEO & Director	1.03M	無	1965
Ms. Elizabeth A. Grammer Esq.	Chief Legal & Administrative Officer and Secretary	668.25k	無	1964
Dr. Laura A. Williams M.D., M.P.H.	Chief Medical Officer	664.81k	無	1964
Mr. Justin A. Renz CPA, MBA	Chief Financial & Operations Officer	623.7k	無	1972
Mr. Robert Felsch	Senior VP of Finance & Chief Accounting Officer	無	無	無
Ms. Caitlin Lowie	Vice President of Corporate Communications & Investor Relations	無	無	無
Mr. Mike Kelliher	Executive Vice President of Corporate Development & Strategy	無	無	1977
Ms. Charon Spencer Sr.	Chief Human Resources Officer	無	無	無
Mr. David P. Rosenbaum	Chief Development Officer	645.4k	無	1961
Mr. Robert C. Blanks	Chief Regulatory Affairs & Quality Assurance Officer	590.8k	無	1960

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

公司管治

截至 2024年5月1日 止，Ardelyx, Inc. 的 ISS 管治質素評分為 8。 Pillar 分數正在審核中：9；董事會：7；股東權利：8；現金賠償：9。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。